BridgeBio Pharma, Inc. (BBIO) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar Call (Transcript)

Core Insights - The presentation focuses on encaleret, a small molecule being developed for autosomal dominant hypocalcemia type 1 (ADH1) [2][3] - The webinar includes insights from key figures in the development of encaleret, including Dr. Rachel Gafni and Dr. Scott Adler [3] Market Opportunity - The company aims to discuss the market potential for ADH1 and the implications of encaleret in addressing this condition [4]